Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 13/20 | 0.69 |
| ▸ | CCKAR | P32238 | 9/20 | 0.69 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.50 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.50 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | BRD2 | P25440 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8711252 | 0.90 | CCKBR (0.65) | CCKBRCCKARSENP1 | |
| SCHEMBL641969 | 0.90 | CCKBR (0.65) | CCKBRCCKARSENP1 | |
| SCHEMBL1574399 | 0.90 | CCKBR (0.65) | CCKBRCCKARSENP1 | |
| SCHEMBL4423335 | 0.89 | CCKBR (0.67) | CCKBRCCKARSENP1BRD4BRD2 | |
| Water SCHEMBL9229371 | 0.89 | CCKBR (0.64) | CCKBRCCKARSENP1 | |
| SCHEMBL9432720 | 0.88 | CCKBR (0.58) | CCKBRCCKARSENP1BRD4BRD2 | |
| SCHEMBL6939944 | 0.88 | CCKBR (0.58) | CCKBRCCKARSENP1BRD4BRD2 | |
| SCHEMBL6939937 | 0.88 | CCKBR (0.58) | CCKBRCCKARSENP1BRD4BRD2 | |
| SCHEMBL1574220 | 0.87 | BRD4 (0.61) | CCKBRCCKARSENP1NOTCH1NOTCH3 | |
| SCHEMBL1574224 | 0.87 | BRD4 (0.61) | CCKBRCCKARSENP1NOTCH1NOTCH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | APP, APBA1, DNPEP | CCKBR 231/4885CCKAR 416/4885SENP1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.